You Chengyu, Li Xianhui, Du Yuelin, Wang Hui, Zhang Xiaojun, Wei Tangqiang, Wang Anguo
Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College, Nanchong, China.
PeerJ. 2021 Sep 28;9:e12248. doi: 10.7717/peerj.12248. eCollection 2021.
To summarize the current evidence on the effects of intra-arterial chemotherapy (IAC) on high-risk non-muscle invasive bladder cancer (NMIBC) and compare oncology results with intravesical chemotherapy (IVC).
We performed a systematic review and cumulative meta-analysis of the primary outcomes of interest by a systematical search of multiple scientific databases in February 2021. The mean difference (MD) and odds ratio (OR) were calculated for continuous and dichotomous variables respectively, with 95% confidence intervals (CIs). The hazard radio (HR) with 95% CIs was used for overall survival (OS), recurrence-free survival (RFS) and progression-free survival (PFS).
A total of six studies with 866 patients were included. For IAC combined with IVC versus IVC alone, statistically significant differences were found regarding tumor recurrence rate (OR: 0.51, 95% CI [0.36∼0.72], = 0.0001), tumor progression rate (OR: 0.47, 95% CI [0.30∼0.72], = 0.0006), tumor-specific death rate (OR: 0.49, 95% CI [0.25∼0.99], = 0.05), PFS (HR: 0.47, 95% CI [0.23∼0.96], = 0.04) and RFS (HR: 0.60, 95% CI [0.41∼0.87], = 0.007). No significant difference between two groups was found for time to first recurrence (MD: 3.27, 95% CI [-2.37∼8.92], = 0.26) and OS (HR: 1.20, 95% CI [0.44∼3.32], = 0.72). For IAC alone versus IVC, There was no statistical difference in the terms of tumor-specific death rate (OR: 0.67, 95% CI [0.29∼1.53], = 0.34), RFS (HR: 0.90, 95% CI [0.56∼1.46], = 0.68) and PFS (HR: 0.71, 95% CI [0.32∼1.55], = 0.39). Adverse events mainly included nausea/vomiting (36.3%), hypoleukemia (19.4%), neutropenia (16.0%), increased creatinine (9.9%), increased alanine aminotransferase (18.7%), and thrombocytopenia (9.9%).
The IAC combined with IVC is a safe and effective treatment for high risk NMIBC, with lower rates of recurrence, progression, tumor-specific death, PFS and RFS, and with minor and tolerable events. The effectiveness of the IAC alone is parallel to the IVC alone.
总结动脉内化疗(IAC)对高危非肌层浸润性膀胱癌(NMIBC)影响的当前证据,并将肿瘤学结果与膀胱内化疗(IVC)进行比较。
我们于2021年2月通过系统检索多个科学数据库,对感兴趣的主要结局进行了系统评价和累积荟萃分析。分别计算连续变量和二分变量的平均差(MD)和比值比(OR),并给出95%置信区间(CI)。总生存(OS)、无复发生存(RFS)和无进展生存(PFS)采用含95%CI的风险比(HR)。
共纳入6项研究,866例患者。IAC联合IVC与单纯IVC相比,在肿瘤复发率(OR:0.51,95%CI[0.36~0.72],P = 0.0001)、肿瘤进展率(OR:0.47,95%CI[0.30~0.72],P = 0.0006)、肿瘤特异性死亡率(OR:0.49,95%CI[0.25~0.99],P = 0.05)、PFS(HR:0.47,95%CI[0.23~0.96],P = 0.04)和RFS(HR:0.60,95%CI[0.41~0.87],P = 0.007)方面存在统计学显著差异。两组在首次复发时间(MD:3.27,95%CI[-2.37~8.92],P = 0.26)和OS(HR:1.20,95%CI[0.44~3.32],P = 0.72)方面未发现显著差异。IAC单药与IVC相比,在肿瘤特异性死亡率(OR:0.67,95%CI[0.29~1.53],P = 0.34)、RFS(HR:0.90,95%CI[0.56~1.46],P = 0.68)和PFS(HR:0.71,95%CI[0.32~1.55],P = 0.39)方面无统计学差异。不良事件主要包括恶心/呕吐(36.3%)、白细胞减少(19.4%)、中性粒细胞减少(16.0%)、肌酐升高(9.9%)、谷丙转氨酶升高(18.7%)和血小板减少(9.9%)。
IAC联合IVC是治疗高危NMIBC的一种安全有效的方法,具有较低的复发率、进展率、肿瘤特异性死亡率、PFS和RFS,且不良事件轻微且可耐受。IAC单药的疗效与IVC单药相当。